Application Nr Approved Date Route Status External Links
NDA209401 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Vyxeos Is Indicated For The Treatment Of Adults With Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (T-Aml) Or Aml With Myelodysplasia-Related Changes (Aml-Mrc). Vyxeos Is A Liposomal Combination Of Daunorubicin, An Anthracycline Topoisomerase Inhibitor, And Cytarabine, A Nucleoside Metabolic Inhibitor, That Is Indicated For The Treatment Of Adults With Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (T-Aml) Or Aml With Myelodysplasia-Related Changes (Aml-Mrc). ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Name Structure ZINC ID(s)
1. Cytarabine CYTARABINE ZINC3795098
2. Daunorubicin DAUNORUBICIN ZINC3917708

Comments